Article thumbnail

Role of zoledronic acid in the prevention and treatment of osteoporosis

By Agnès Räkel, Andrée Boucher and Louis-Georges Ste-Marie

Abstract

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3095556
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A model of lifetime osteoporosis impact.
  2. (2007). A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther.
  3. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
  4. Acute renal failure in cancer patients. Oncology (Williston Park).
  5. (2006). Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin
  6. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
  7. (2001). Anticancer drug-induced kidney disorders. Drug Saf.
  8. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate.
  9. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies.
  10. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.
  11. (2010). Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
  12. (2010). clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.
  13. (2002). clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
  14. Compliance with drug therapies for the treatment and prevention of osteoporosis.
  15. Current and projected rates of hip fracture in Canada.
  16. (2009). Effect of once- yearly i.v. zoledronic acid in men after hip fracture: results from the HORIZON-Recurrent Fracture Trial. Osteoporos Int.
  17. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
  18. (2010). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int.
  19. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
  20. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
  21. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
  22. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
  23. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics.
  24. (2008). Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation;
  25. (2010). Fracture incidence in HIV-infected women: results from the Women’s Interagency
  26. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
  27. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
  28. (2010). Information on bisphosphonates (marketed as Actonel,
  29. (1999). Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int.
  30. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
  31. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
  32. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
  33. (2008). Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma.
  34. (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med.
  35. (2006). Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
  36. of Health Consensus Development Panel on Osteoporosis, Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy.
  37. (2011). Once-yearly IV zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosis. In:
  38. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
  39. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
  40. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
  41. Predictive value of BMD for hip and other fractures.
  42. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory
  43. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
  44. (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate
  45. Recommendations for bone mineral density reporting in Canada.
  46. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
  47. (2000). Risk of mortality following clinical fractures. Osteoporos Int.
  48. (1999). Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study.
  49. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
  50. (1995). Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther.
  51. (2010). Subtrochanteric fractures after long-term treatment with bisphosphonates: a
  52. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
  53. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
  54. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.
  55. (2007). The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis Int.
  56. (2011). Updated Renal Safety Information on
  57. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture.
  58. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
  59. (2009). Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol.
  60. (2003). Zoledronic acid: a new parenteral bisphosphonate. Clin Ther.